Matches in SemOpenAlex for { <https://semopenalex.org/work/W2018108071> ?p ?o ?g. }
- W2018108071 endingPage "669" @default.
- W2018108071 startingPage "662" @default.
- W2018108071 abstract "2-Deoxy-2-[18F]fluoro-d-glucose ([18F]FDG) has extensively been used for clinical diagnosis, staging, and therapy monitoring of cancer and other diseases. Nonradioactive glucose analogues enabling the screening of the glucose metabolic rate of tumors are of particular interest for anticancer drug development. A nonradioactive fluorescent deoxyglucose analogue may have many applications for both imaging of tumors and monitoring therapeutic efficacy of drugs in living animals and may eventually translate to clinical applications. We found that a fluorescent 2-deoxyglucose analogue, 2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]-2-deoxy-d-glucose (2-NBDG), can be delivered in several tumor cells via the glucose transporters (GLUTs). We therefore conjugated d-glucosamine with a near-infrared (NIR) fluorphor Cy5.5 and tested the feasibility of the Cy5.5−d-glucosamine (Cy5.5−2DG) conjugate for NIR fluorescence imaging of tumors in a preclinical xenograft animal model. Cy5.5−2DG was prepared by conjugating Cy5.5 monofunctional N-hydroxysuccinimide ester (Cy5.5−NHS) and d-glucosamine followed by high-performance liquid chromatography purification. The accumulation of Cy5.5−2DG and Cy5.5−NHS in different tumor cell lines at 37 and 4 °C were imaged using a fluorescence microscope. Tumor targeting and retention of Cy5.5−2DG and Cy5.5−NHS in a subcutaneous U87MG glioma and A375M melanoma tumor model were evaluated and quantified by a Xenogen IVIS 200 optical cooled charged-coupled device system. Fluorescence microscopy imaging shows that Cy5.5−2DG and Cy5.5−NHS are taken up and trapped by a variety of tumor cell lines at 37 °C incubation, while they exhibit marginal uptake at 4 °C. The tumor cell uptake of Cy5.5−2DG cannot be blocked by the 50 mM d-glucose, suggesting that Cy5.5−2DG may not be delivered in tumor cells by GLUTs. U87MG and A375M tumor localization was clearly visualized in living mice with both NIR fluorescent probes. Tumor/muscle contrast was clearly visible as early as 30 min postinjection (pi), and the highest U87MG tumor/muscle ratios of 2.81 ± 0.10 and 3.34 ± 0.23 were achieved 24 h pi for Cy5.5−2DG and Cy5.5−NHS, respectively. While as a comparison, the micropositron emission tomography imaging study shows that [18F]FDG preferentially localizes to the U87MG tumor, with resulting tumor/muscle ratios ranging from 3.89 to 4.08 after 30 min to 2 h postadministration of the probe. In conclusion, the NIR fluorescent glucose analogues, Cy5.5−2DG and Cy5.5−NHS, both demonstrate tumor-targeting abilities in cell culture and living mice. More studies are warranted to further explore their application for optical tumor imaging. To develop NIR glucose analogues with the ability to target GLUTs/hexokinase, it is highly important to select NIR dyes with a reasonable molecular size." @default.
- W2018108071 created "2016-06-24" @default.
- W2018108071 creator A5003581995 @default.
- W2018108071 creator A5015719655 @default.
- W2018108071 creator A5018249388 @default.
- W2018108071 creator A5019955301 @default.
- W2018108071 creator A5047820662 @default.
- W2018108071 creator A5061338137 @default.
- W2018108071 creator A5075963891 @default.
- W2018108071 date "2006-04-21" @default.
- W2018108071 modified "2023-10-13" @default.
- W2018108071 title "Near-Infrared Fluorescent Deoxyglucose Analogue for Tumor Optical Imaging in Cell Culture and Living Mice" @default.
- W2018108071 cites W1553198783 @default.
- W2018108071 cites W1962079151 @default.
- W2018108071 cites W1970857836 @default.
- W2018108071 cites W1971145143 @default.
- W2018108071 cites W1975288104 @default.
- W2018108071 cites W1980797590 @default.
- W2018108071 cites W1984476260 @default.
- W2018108071 cites W1992351068 @default.
- W2018108071 cites W1994759929 @default.
- W2018108071 cites W2005460629 @default.
- W2018108071 cites W2024648928 @default.
- W2018108071 cites W2038518285 @default.
- W2018108071 cites W2040859219 @default.
- W2018108071 cites W2041073976 @default.
- W2018108071 cites W2042414217 @default.
- W2018108071 cites W2043680485 @default.
- W2018108071 cites W2044195880 @default.
- W2018108071 cites W2061782980 @default.
- W2018108071 cites W2063962920 @default.
- W2018108071 cites W2089544915 @default.
- W2018108071 cites W2106736701 @default.
- W2018108071 cites W2118783921 @default.
- W2018108071 cites W2119507443 @default.
- W2018108071 cites W2123021242 @default.
- W2018108071 cites W2125760670 @default.
- W2018108071 cites W2140007438 @default.
- W2018108071 cites W2151153432 @default.
- W2018108071 cites W2163180789 @default.
- W2018108071 cites W2185893808 @default.
- W2018108071 cites W2210289629 @default.
- W2018108071 cites W2225412566 @default.
- W2018108071 cites W2318354309 @default.
- W2018108071 cites W2324850882 @default.
- W2018108071 cites W2414425146 @default.
- W2018108071 doi "https://doi.org/10.1021/bc050345c" @default.
- W2018108071 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3191878" @default.
- W2018108071 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16704203" @default.
- W2018108071 hasPublicationYear "2006" @default.
- W2018108071 type Work @default.
- W2018108071 sameAs 2018108071 @default.
- W2018108071 citedByCount "168" @default.
- W2018108071 countsByYear W20181080712012 @default.
- W2018108071 countsByYear W20181080712013 @default.
- W2018108071 countsByYear W20181080712014 @default.
- W2018108071 countsByYear W20181080712015 @default.
- W2018108071 countsByYear W20181080712016 @default.
- W2018108071 countsByYear W20181080712017 @default.
- W2018108071 countsByYear W20181080712018 @default.
- W2018108071 countsByYear W20181080712019 @default.
- W2018108071 countsByYear W20181080712020 @default.
- W2018108071 countsByYear W20181080712021 @default.
- W2018108071 countsByYear W20181080712022 @default.
- W2018108071 countsByYear W20181080712023 @default.
- W2018108071 crossrefType "journal-article" @default.
- W2018108071 hasAuthorship W2018108071A5003581995 @default.
- W2018108071 hasAuthorship W2018108071A5015719655 @default.
- W2018108071 hasAuthorship W2018108071A5018249388 @default.
- W2018108071 hasAuthorship W2018108071A5019955301 @default.
- W2018108071 hasAuthorship W2018108071A5047820662 @default.
- W2018108071 hasAuthorship W2018108071A5061338137 @default.
- W2018108071 hasAuthorship W2018108071A5075963891 @default.
- W2018108071 hasBestOaLocation W20181080712 @default.
- W2018108071 hasConcept C121332964 @default.
- W2018108071 hasConcept C134306372 @default.
- W2018108071 hasConcept C169274487 @default.
- W2018108071 hasConcept C185592680 @default.
- W2018108071 hasConcept C197336794 @default.
- W2018108071 hasConcept C2777658100 @default.
- W2018108071 hasConcept C2778125326 @default.
- W2018108071 hasConcept C2780909259 @default.
- W2018108071 hasConcept C33923547 @default.
- W2018108071 hasConcept C502942594 @default.
- W2018108071 hasConcept C54355233 @default.
- W2018108071 hasConcept C55493867 @default.
- W2018108071 hasConcept C57477423 @default.
- W2018108071 hasConcept C62520636 @default.
- W2018108071 hasConcept C81885089 @default.
- W2018108071 hasConcept C86803240 @default.
- W2018108071 hasConcept C91881484 @default.
- W2018108071 hasConceptScore W2018108071C121332964 @default.
- W2018108071 hasConceptScore W2018108071C134306372 @default.
- W2018108071 hasConceptScore W2018108071C169274487 @default.
- W2018108071 hasConceptScore W2018108071C185592680 @default.
- W2018108071 hasConceptScore W2018108071C197336794 @default.
- W2018108071 hasConceptScore W2018108071C2777658100 @default.
- W2018108071 hasConceptScore W2018108071C2778125326 @default.